Recent Applications of Lung Organoid and Lung-on-a-Chip Technologies for Evaluating the Toxicity of Fine Particulate Matter.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026
   Review
2. Lung organoids for respiratory diseases: overcoming translational hurdles in drug discovery and safety assessment.Frontiers in bioengineering and biotechnology · 2026
   Review
3. Development, propagation and characterization of human somatic cell-derived bronchial organoids as model system for airway diseases - A practical guide.Frontiers in allergy · 2026
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as